How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
33
ESLOY Quote, Financials, Valuation and Earnings
Last price:
$152.01
Seasonality move
:
6.38%
Day range:
$151.40 - $153.36
52-week range:
$126.47 - $186.81
Dividend yield:
1.48%
P/E ratio:
56.68x
P/S ratio:
4.74x
P/B ratio:
45.05x
Volume:
69.7K
Avg. volume:
82.9K
1-year change:
7.44%
Market cap:
$140.2B
Revenue:
$28.7B
EPS (TTM):
$2.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ESLOY
EssilorLuxottica SA
|
-- | -- | -- | -- | -- |
|
CLLS
Cellectis SA
|
$11.9M | -$0.11 | -5.7% | -56.58% | $7.00 |
|
DBVT
DBV Technologies SA
|
$1.3M | -$0.22 | -- | -86.12% | $40.29 |
|
IPHA
Innate Pharma SA
|
$2.6M | -- | -- | -- | $5.75 |
|
IVA
Inventiva SA
|
-- | -$0.18 | -- | -- | $15.48 |
|
NBTX
Nanobiotix SA
|
-- | -- | -- | -- | $23.61 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ESLOY
EssilorLuxottica SA
|
$152.01 | -- | $140.2B | 56.68x | $2.25 | 1.48% | 4.74x |
|
CLLS
Cellectis SA
|
$3.50 | $7.00 | $351.1M | -- | $0.00 | 0% | 4.35x |
|
DBVT
DBV Technologies SA
|
$21.46 | $40.29 | $587.2M | -- | $0.00 | 0% | -- |
|
IPHA
Innate Pharma SA
|
$1.78 | $5.75 | $166.8M | -- | $0.00 | 0% | 22.99x |
|
IVA
Inventiva SA
|
$5.95 | $15.48 | $867.9M | -- | $0.00 | 0% | 34.64x |
|
NBTX
Nanobiotix SA
|
$21.73 | $23.61 | $1.1B | -- | $0.00 | 0% | 30.31x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ESLOY
EssilorLuxottica SA
|
21.86% | 0.279 | -- | 0.63x |
|
CLLS
Cellectis SA
|
54.27% | 0.329 | 41.7% | 1.35x |
|
DBVT
DBV Technologies SA
|
23.24% | -3.992 | 5.85% | 1.41x |
|
IPHA
Innate Pharma SA
|
55.22% | -0.417 | -- | 2.76x |
|
IVA
Inventiva SA
|
-145.15% | -1.178 | 32.05% | 0.43x |
|
NBTX
Nanobiotix SA
|
195.9% | 4.378 | 20.12% | 1.38x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ESLOY
EssilorLuxottica SA
|
-- | -- | 4.89% | 6.07% | -- | -- |
|
CLLS
Cellectis SA
|
$30M | $5.9M | -15.69% | -31.08% | 16.76% | -$4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
IPHA
Innate Pharma SA
|
-- | -- | -39.78% | -72.79% | -- | -- |
|
IVA
Inventiva SA
|
-- | -- | -- | -- | -- | -- |
|
NBTX
Nanobiotix SA
|
-- | -- | -161.14% | -- | -- | -- |
EssilorLuxottica SA vs. Competitors
-
Which has Higher Returns ESLOY or CLLS?
Cellectis SA has a net margin of -- compared to EssilorLuxottica SA's net margin of 1.68%. EssilorLuxottica SA's return on equity of 6.07% beat Cellectis SA's return on equity of -31.08%.
Company Gross Margin Earnings Per Share Invested Capital ESLOYEssilorLuxottica SA-- -- $57.4B CLLSCellectis SA85.76% $0.01 $219.7M -
What do Analysts Say About ESLOY or CLLS?
EssilorLuxottica SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Cellectis SA has an analysts' consensus of $7.00 which suggests that it could grow by 100%. Given that Cellectis SA has higher upside potential than EssilorLuxottica SA, analysts believe Cellectis SA is more attractive than EssilorLuxottica SA.
Company Buy Ratings Hold Ratings Sell Ratings ESLOYEssilorLuxottica SA0 0 0 CLLSCellectis SA2 2 0 -
Is ESLOY or CLLS More Risky?
EssilorLuxottica SA has a beta of 1.023, which suggesting that the stock is 2.265% more volatile than S&P 500. In comparison Cellectis SA has a beta of 2.833, suggesting its more volatile than the S&P 500 by 183.275%.
-
Which is a Better Dividend Stock ESLOY or CLLS?
EssilorLuxottica SA has a quarterly dividend of $2.25 per share corresponding to a yield of 1.48%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EssilorLuxottica SA pays 57.66% of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend. EssilorLuxottica SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESLOY or CLLS?
EssilorLuxottica SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $35M. EssilorLuxottica SA's net income of -- is lower than Cellectis SA's net income of $586.4K. Notably, EssilorLuxottica SA's price-to-earnings ratio is 56.68x while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EssilorLuxottica SA is 4.74x versus 4.35x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESLOYEssilorLuxottica SA4.74x 56.68x -- -- CLLSCellectis SA4.35x -- $35M $586.4K
-
Which has Higher Returns ESLOY or DBVT?
DBV Technologies SA has a net margin of -- compared to EssilorLuxottica SA's net margin of --. EssilorLuxottica SA's return on equity of 6.07% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital ESLOYEssilorLuxottica SA-- -- $57.4B DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About ESLOY or DBVT?
EssilorLuxottica SA has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of $40.29 which suggests that it could grow by 87.72%. Given that DBV Technologies SA has higher upside potential than EssilorLuxottica SA, analysts believe DBV Technologies SA is more attractive than EssilorLuxottica SA.
Company Buy Ratings Hold Ratings Sell Ratings ESLOYEssilorLuxottica SA0 0 0 DBVTDBV Technologies SA4 0 1 -
Is ESLOY or DBVT More Risky?
EssilorLuxottica SA has a beta of 1.023, which suggesting that the stock is 2.265% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.978, suggesting its less volatile than the S&P 500 by 197.819%.
-
Which is a Better Dividend Stock ESLOY or DBVT?
EssilorLuxottica SA has a quarterly dividend of $2.25 per share corresponding to a yield of 1.48%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EssilorLuxottica SA pays 57.66% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. EssilorLuxottica SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESLOY or DBVT?
EssilorLuxottica SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. EssilorLuxottica SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, EssilorLuxottica SA's price-to-earnings ratio is 56.68x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EssilorLuxottica SA is 4.74x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESLOYEssilorLuxottica SA4.74x 56.68x -- -- DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns ESLOY or IPHA?
Innate Pharma SA has a net margin of -- compared to EssilorLuxottica SA's net margin of --. EssilorLuxottica SA's return on equity of 6.07% beat Innate Pharma SA's return on equity of -72.79%.
Company Gross Margin Earnings Per Share Invested Capital ESLOYEssilorLuxottica SA-- -- $57.4B IPHAInnate Pharma SA-- -- $68.9M -
What do Analysts Say About ESLOY or IPHA?
EssilorLuxottica SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Innate Pharma SA has an analysts' consensus of $5.75 which suggests that it could grow by 223.03%. Given that Innate Pharma SA has higher upside potential than EssilorLuxottica SA, analysts believe Innate Pharma SA is more attractive than EssilorLuxottica SA.
Company Buy Ratings Hold Ratings Sell Ratings ESLOYEssilorLuxottica SA0 0 0 IPHAInnate Pharma SA3 1 0 -
Is ESLOY or IPHA More Risky?
EssilorLuxottica SA has a beta of 1.023, which suggesting that the stock is 2.265% more volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.017, suggesting its less volatile than the S&P 500 by 101.669%.
-
Which is a Better Dividend Stock ESLOY or IPHA?
EssilorLuxottica SA has a quarterly dividend of $2.25 per share corresponding to a yield of 1.48%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EssilorLuxottica SA pays 57.66% of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend. EssilorLuxottica SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESLOY or IPHA?
EssilorLuxottica SA quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. EssilorLuxottica SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, EssilorLuxottica SA's price-to-earnings ratio is 56.68x while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EssilorLuxottica SA is 4.74x versus 22.99x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESLOYEssilorLuxottica SA4.74x 56.68x -- -- IPHAInnate Pharma SA22.99x -- -- --
-
Which has Higher Returns ESLOY or IVA?
Inventiva SA has a net margin of -- compared to EssilorLuxottica SA's net margin of --. EssilorLuxottica SA's return on equity of 6.07% beat Inventiva SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ESLOYEssilorLuxottica SA-- -- $57.4B IVAInventiva SA-- -- -$34.6M -
What do Analysts Say About ESLOY or IVA?
EssilorLuxottica SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Inventiva SA has an analysts' consensus of $15.48 which suggests that it could grow by 160.23%. Given that Inventiva SA has higher upside potential than EssilorLuxottica SA, analysts believe Inventiva SA is more attractive than EssilorLuxottica SA.
Company Buy Ratings Hold Ratings Sell Ratings ESLOYEssilorLuxottica SA0 0 0 IVAInventiva SA10 0 0 -
Is ESLOY or IVA More Risky?
EssilorLuxottica SA has a beta of 1.023, which suggesting that the stock is 2.265% more volatile than S&P 500. In comparison Inventiva SA has a beta of 0.720, suggesting its less volatile than the S&P 500 by 28%.
-
Which is a Better Dividend Stock ESLOY or IVA?
EssilorLuxottica SA has a quarterly dividend of $2.25 per share corresponding to a yield of 1.48%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EssilorLuxottica SA pays 57.66% of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend. EssilorLuxottica SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESLOY or IVA?
EssilorLuxottica SA quarterly revenues are --, which are smaller than Inventiva SA quarterly revenues of --. EssilorLuxottica SA's net income of -- is lower than Inventiva SA's net income of --. Notably, EssilorLuxottica SA's price-to-earnings ratio is 56.68x while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EssilorLuxottica SA is 4.74x versus 34.64x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESLOYEssilorLuxottica SA4.74x 56.68x -- -- IVAInventiva SA34.64x -- -- --
-
Which has Higher Returns ESLOY or NBTX?
Nanobiotix SA has a net margin of -- compared to EssilorLuxottica SA's net margin of --. EssilorLuxottica SA's return on equity of 6.07% beat Nanobiotix SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ESLOYEssilorLuxottica SA-- -- $57.4B NBTXNanobiotix SA-- -- $24.3M -
What do Analysts Say About ESLOY or NBTX?
EssilorLuxottica SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nanobiotix SA has an analysts' consensus of $23.61 which suggests that it could grow by 8.65%. Given that Nanobiotix SA has higher upside potential than EssilorLuxottica SA, analysts believe Nanobiotix SA is more attractive than EssilorLuxottica SA.
Company Buy Ratings Hold Ratings Sell Ratings ESLOYEssilorLuxottica SA0 0 0 NBTXNanobiotix SA5 0 0 -
Is ESLOY or NBTX More Risky?
EssilorLuxottica SA has a beta of 1.023, which suggesting that the stock is 2.265% more volatile than S&P 500. In comparison Nanobiotix SA has a beta of 0.700, suggesting its less volatile than the S&P 500 by 30.038%.
-
Which is a Better Dividend Stock ESLOY or NBTX?
EssilorLuxottica SA has a quarterly dividend of $2.25 per share corresponding to a yield of 1.48%. Nanobiotix SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EssilorLuxottica SA pays 57.66% of its earnings as a dividend. Nanobiotix SA pays out -- of its earnings as a dividend. EssilorLuxottica SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESLOY or NBTX?
EssilorLuxottica SA quarterly revenues are --, which are smaller than Nanobiotix SA quarterly revenues of --. EssilorLuxottica SA's net income of -- is lower than Nanobiotix SA's net income of --. Notably, EssilorLuxottica SA's price-to-earnings ratio is 56.68x while Nanobiotix SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EssilorLuxottica SA is 4.74x versus 30.31x for Nanobiotix SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESLOYEssilorLuxottica SA4.74x 56.68x -- -- NBTXNanobiotix SA30.31x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
59
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
58
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
61
SLAB alert for Feb 5
Silicon Laboratories, Inc. [SLAB] is up 0.91% over the past day.
Buy
73
ENPH alert for Feb 6
Enphase Energy, Inc. [ENPH] is down 8.53% over the past day.
Sell
25
MRCY alert for Feb 5
Mercury Systems, Inc. [MRCY] is up 2.61% over the past day.
